Bart Wuurman
Algemeen Directeur bij Hercules Pharmaceuticals BV
Profiel
Bart Wuurman currently works at Hercules Pharmaceuticals BV, as Chief Executive Officer & Director and Apaxen SA, as Chief Executive Officer from 2020.
Dr. Wuurman also formerly worked at De Novo Pharmaceuticals Ltd., as Chief Executive Officer, AM-Pharma BV, as Chief Executive Officer, LanthioPep BV, as Chief Executive Officer, Lanthio Pharma BV, as Chief Executive Officer, Sarossa Capital Ltd., as Director-Business Development, Medeva Plc, as Director-Business Development, and Organon BioSciences NV, as Director-Business Development.
Actieve functies van Bart Wuurman
Bedrijven | Functie | Begin |
---|---|---|
Hercules Pharmaceuticals BV
Hercules Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Hercules Pharmaceuticals BV operates as biopharmaceutical company, which develops oral and non-toxic drug therapy for chronic treatment of patients with triple negative breast cancer. The company was founded by David Sherr in 2013 and is headquartered in Leiden, the Netherlands. | Algemeen Directeur | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Algemeen Directeur | 01-09-2020 |
Eerdere bekende functies van Bart Wuurman
Bedrijven | Functie | Einde |
---|---|---|
LanthioPep BV
LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Algemeen Directeur | - |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Algemeen Directeur | - |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | President | - |
De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | President | - |
Sarossa Capital Ltd.
Sarossa Capital Ltd. Financial ConglomeratesFinance Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 9 |
---|---|
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Health Technology |
Medeva Plc | Health Technology |
Sarossa Capital Ltd.
Sarossa Capital Ltd. Financial ConglomeratesFinance Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom. | Finance |
De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
LanthioPep BV
LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Health Technology |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
Hercules Pharmaceuticals BV
Hercules Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Hercules Pharmaceuticals BV operates as biopharmaceutical company, which develops oral and non-toxic drug therapy for chronic treatment of patients with triple negative breast cancer. The company was founded by David Sherr in 2013 and is headquartered in Leiden, the Netherlands. | Health Technology |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |